[North Carolina session] Meet with Johnson & Johnson Innovation
[North Carolina session] Meet with Johnson & Johnson Innovation
North Carolina Biotechnology Center, Auditorium , 15 T.W. Alexander Drive , Research Triangle Park , NC 27709
April 12, 2017 from 12:30 PM to 15:00 PM (EDT)
$10 - $35
How can Johnson & Johnson Innovation (JJI) help you reach your goals? We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a diverse team of science and transaction experts whose goal is to find high potential early-stage innovation and, if on strategy and a fit for Johnson & Johnson, create customized deal structures to help accelerate the science to the patient.
We are also supporting innovation in major life science clusters through the life science incubator, Johnson & Johnson Innovation, JLABS, with the ultimate aim of enabling commercialization of new healthcare solutions for patients. At Johnson & Johnson Innovation, we recognize that a good idea can come from anywhere, and we work with partners at all stages of research and development to nurture the innovation ecosystem and propel the best ideas into solutions for patients.
On April 12, hear from Johnson & Johnson Innovation leaders as they provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives.
Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation.
Areas of interest include:
- Baby care
- Compromised skin
- Feminine personal care
- Oral care
- Vision care
- Infectious Diseases & Vaccines
- Cardiovascular & Metabolism
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
12:30 PM | Networking Lunch
1:00-5:00 PM | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on March 14.
Ibraheem Badejo | Senior Director, New Ventures, Johnson & Johnson Innovation read bio»
Dana Deardorff | Senior Director, New Ventures, Johnson & Johnson Innovation read bio»
Stefanie Dhanda | Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation read bio»
Nicola La Monica | Senior Director, Infectious Disease and Vaccines Scientific Innovation, Janssen R&D read bio»
Samantha Lifson | Innovation Activation Specialist, Johnson & Johnson Innovation, JLABS read bio»
Kuldeep Neote | Senior Director, New Ventures, Johnson & Johnson Innovationread bio»
Bob Radinsky | Vice President, Oncology Scientific Innovation, Janssen R&D read bio»
Eric Schaeffer | Senior Director, Neuroscience External Innovation, Janssen R&D read bio»
Presentation & Lunch
FREE | General Public
FREE | Onsite
Includes presentation, Q&A, and lunch. All attendees must register, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on April 11(or sold out).
FREE | Application
FREE | Accepted Companies
Companies must apply for a one-on-one meeting ahead of time. The one-on-one application period ends on March 14. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
North Carolina Biotechnology Center, Auditorium
15 T.W. Alexander Drive
Research Triangle Park, NC 27709
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Participating Representatives' Biographies:
Ibraheem Badejo, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.
Connect with Ibraheem:
Dana Deardorff, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Dana Deardorff, Ph.D. recently joined Johnson & Johnson Innovation as the Senior Director of New Ventures for medical devices. In this role, Dana is responsible for developing and investing in early-stage technologies of strategic interest across the medical device sector within J&J. Dana has over 20 years of experience in the medtech industry in various roles bridging technology and business. Previously he worked for Covidien in several leadership positions including VP of Advanced Technology, Strategy & Portfolio Management, and Business Development. Dana has also been an entrepreneur, starting multiple companies as a co-founder and leading technology and product development activities. Most recently he served as an Entrepreneur-in-Residence and advisor to the University of Illinois, helping to evaluate and accelerate the commercial potential of innovative technologies. Dana has a joint doctorate in biomedical engineering from UC-Berkeley and UC-San Francisco and a bachelor's degree in physics from Illinois Wesleyan University.
Connect with Dana:
Stefanie Dhanda | Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation
Stefanie is Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation, Boston. Stefanie leads Consumer sector efforts to grow and maintain a portfolio of innovative external partnerships, collaborations and investments for the benefit of J&J's Consumer businesses, which currently reach across broad and diverse sectors such as oral care, compromised skin, baby and maternal health, personal care and beauty, an OTC platform anchored in pain relief, cough/cold, and digestive health, as well as digital health platforms. Previously, Stefanie was a Managing Director at Stonebridge Associates, a Boston-based investment banking firm that she helped found in 1996. She has over 20 years of experience in providing strategic and financial advisory services to small and midsized family-owned and growth companies in the consumer and healthcare sectors. Within that role she led mergers and acquisitions engagements, raised capital, defined business and financial strategy, performed complex due diligence and negotiated strategic alliances. In addition, Stefanie was independently consulting with several innovative startup and early-stage companies focused on the nutrition, health and wellness sector. Prior to Stonebridge, she worked at the Bank of New York. Stefanie has a Bachelor of Science degree in Finance and Operations & Strategic Management from Boston College
Connect with Stefanie:
Nicola La Monica | Senior Director, Infectious Disease and Vaccines Scientific Innovation, Janssen R&D
Nicola is Senior Director of Infectious Diseases and Vaccines Scientific Innovation at Johnson & Johnson Innovation, Boston.
From 2009 to 2012, Nicola was at Idera Pharmaceuticals, where he was Vice President of biology. From 1991 to 2009, he was the Director of Antiviral Research at the Istituto di Ricerche di Biologia Molecolare (IRBM), Rome, Italy, a research site of Merck Research Laboratories. Prior to that, he held the positions of Director of Oncology and Director of Cancer Immunology and Genomics.
During his career, Nicola has led drug discovery efforts for the treatment of Hepatitis C virus infections and oncology, as well as development programs for cancer immunotherapy. Nicola earned his BA degree in Biology from the University of Rochester in 1982. His graduate studies were completed at Columbia University, where he earned a PhD in Microbiology in 1988.
Connect with Nicola:
Samantha Lifson | Innovation Activation Specialist, Johnson & Johnson Innovation, JLABS
Samantha is the Marketing and Events Manager with Johnson & Johnson Innovation, JLABS, working out of the Boston Innovation Center. Sammy is responsible for event planning and digital marketing on the East Coast. Her role includes coordinating high-quality, diverse and distinctive programming ranging from one-on-one investor meetings, workshops and large panel series to networking and social events.
Prior to joining JLABS, Sammy served as the Community & Online Organizing Coordinator at Planned Parenthood Hudson Peconic, assisting with communications, government relations, and social media advocacy. She holds a B.A. in Advertising and Women’s & Gender Studies from Syracuse University.
Connect with Samantha:
Kuldeep Neote, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology. A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech. Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff's disease.
Connect with Kuldeep:
Robert Radinsky, Ph.D. | Vice President, Oncology Scientific Innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson
Robert Radinsky, Ph.D. is Vice President, Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in Johnson & Johnson Innovation, Boston. In this role, he is responsible for identifying and fostering innovation in the region that supports the Oncology Therapeutic Area strategies. Prior to this role, he led Discovery Research, Oncology, for Janssen. Robert has had a very successful oncology research career in both academics and industry. Prior to joining Janssen, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug for the treatment of colorectal carcinoma. Before joining the industry 14 years ago, Robert was on the faculty at The University of Texas MD Anderson Cancer Center in Houston, first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology, and eventually becoming a tenured Associate Professor in the Department of Cancer Biology. He continued as an Adjunct Professor at the MD Anderson Cancer Center after joining the industry. Robert has published more than 130 peer-reviewed articles, holds multiple patents, and is a present/past member of numerous societies, including the American Association for Cancer Research, Board of Directors for the Metastasis Research Society, the American Association for the Advancement of Science, the Scientific Advisory Board and the Aspen Cancer Conference. He is an Editorial Member and/or ad hoc reviewer for more than 20 scientific journals and has served on review panels for a number of granting agencies, including the National Institutes of Health/National Cancer Institute, the Department of Defense Prostate and Breast Cancer Research Programs, and the Veterans Administration Merit Review Board. Robert earned his doctorate in Molecular Biology and Microbiology from Case Western Reserve University School of Medicine in Cleveland, Ohio.
Connect with Bob:
Eric Schaeffer, Ph.D. | Senior Director, Neuroscience External Innovation, Janssen R&D
Eric Schaeffer has more than 20 years of experience in the pharmaceutical industry, and has delivered multiple drug candidates to the clinic in both large and small company environments. Eric has an extensive background in the biology and pharmacology of CNS disorders including Alzheimer's disease, major depressive disorder, bipolar disorder and schizophrenia. In his current role at Janssen Eric is responsible for establishing and managing external partnerships in the areas of Mood Disorders and Alzheimer's disease. Previous roles held by Eric include Senior Director of Neuroscience Discovery at Pfizer where he was responsible for leading preclinical pharmacology, Director of Neuropharmacology at CHDI where he was responsible for initiating and managing biotech and academic partnerships focused on Huntington's disease and Director of Clinical Biomarkers at Bristol-Myers Squibb where he was responsible for developing the translational strategies for early clinical programs in the areas of schizophrenia, depression and neuromuscular diseases. Eric received his PhD from the Albert Einstein College of Medicine, and did postdoctoral work at MIT and Rockefeller University prior to initiating a career in the pharmaceutical industry.